Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H C Falkson

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1991
Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanomaC I Falkson, G Falkson, H C Falkson
American Journal of Clinical Oncology|August 1, 1988
High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancerC I Falkson, H C Falkson, G Falkson
The Journal of Steroid Biochemistry and Molecular Biology|September 1, 1992
Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancerG Falkson, J I Raats, H C Falkson
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|January 19, 1991
Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patientsB L Rapoport, H C Falkson, G Falkson
Investigational New Drugs|July 1, 1989
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protectorC I Falkson, H C Falkson, G Falkson
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancerC I Falkson, H C Falkson, G Falkson
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1991
Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelinC I Falkson, G Falkson, H C Falkson
Investigational New Drugs|November 1, 1990
High versus low dose granisetron, a selective 5HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomitingH C Falkson, C I Falkson, G Falkson
Drugs & Aging|March 1, 1993
Postmenopausal breast cancer. Drug therapy in the 1990sC I Falkson, G Falkson, H C Falkson
Cancer Treatment Reports|February 1, 1979
Acute leukemia as a complication of long-term treatment of advanced breast cancerM A Portugal, H C Falkson, K Stevens, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1991
Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanomaC I Falkson, G Falkson, H C Falkson
American Journal of Clinical Oncology|August 1, 1988
High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancerC I Falkson, H C Falkson, G Falkson
The Journal of Steroid Biochemistry and Molecular Biology|September 1, 1992
Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancerG Falkson, J I Raats, H C Falkson
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|January 19, 1991
Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patientsB L Rapoport, H C Falkson, G Falkson
Investigational New Drugs|July 1, 1989
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protectorC I Falkson, H C Falkson, G Falkson
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancerC I Falkson, H C Falkson, G Falkson
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1991
Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelinC I Falkson, G Falkson, H C Falkson
Investigational New Drugs|November 1, 1990
High versus low dose granisetron, a selective 5HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomitingH C Falkson, C I Falkson, G Falkson
Drugs & Aging|March 1, 1993
Postmenopausal breast cancer. Drug therapy in the 1990sC I Falkson, G Falkson, H C Falkson
Cancer Treatment Reports|February 1, 1979
Acute leukemia as a complication of long-term treatment of advanced breast cancerM A Portugal, H C Falkson, K Stevens, et al.
Pageof 6